Early detection and longitudinal follow-up of precursor states enable earlier MM diagnosis and reduce myeloma-related complications
Target Population
Patients with precursor plasma cell disorders (MGUS, smoldering multiple myeloma, solitary plasmacytoma) progressing to MM
Care Setting
Tertiary hospital hematology clinics with structured clinical follow-up
Key Highlights
Patients with prior precursor plasma cell disorder (pPCD) diagnosis had significantly shorter symptom duration before MM diagnosis compared to those without prior PCD.
pPCD patients showed lower rates of hypercalcemia, renal insufficiency, anemia, osteolytic lesions, bone pain, pathologic fractures, cord compression, dialysis, and transfusions at MM diagnosis.
Prior PCD diagnosis was associated with a 71% reduction in odds of presenting with clinically significant myeloma-defining events at MM diagnosis after adjusting for age and sex.
Guideline-Based Recommendations
Diagnosis
Identify and risk stratify precursor plasma cell disorders (MGUS, SMM) using monoclonal protein and free light chain data.
Use cross-sectional imaging (MRI, PET/CT, whole body CT) to assess for bone lesions in SMM patients.
Exclude high-risk SMM patients from observational monitoring due to recent evidence supporting early therapy.
Management
Engage patients with precursor plasma cell disorders in regular hematology follow-up to enable early detection of MM progression.
Initiate timely therapy upon MM diagnosis to prevent irreversible end-organ damage.
Monitoring & Follow-up
Monitor symptom onset and laboratory markers closely in patients with precursor plasma cell disorders.
Schedule clinical hematology visits at intervals appropriate to risk stratification (median intervals ranged from 3.6 to 9 months).
Risks
Patients without prior PCD diagnosis are at higher risk of presenting with advanced MM complications including dialysis, fractures, spinal cord compression, hypercalcemia, and need for transfusions.
Delayed diagnosis in nPCD patients leads to increased healthcare utilization including emergency visits and hospitalizations.
Patient & Prescribing Data
MM patients with or without prior diagnosis of precursor plasma cell disorders
Patients with prior PCD diagnosis tend to present with earlier stage MM and fewer complications, suggesting benefits of early detection and monitoring on treatment outcomes.
Clinical Best Practices
Implement structured clinical follow-up for patients with MGUS and low/intermediate risk SMM to facilitate earlier MM diagnosis.
Use comprehensive risk stratification and imaging to guide monitoring frequency and intervention timing.
Educate patients on symptom awareness to reduce time from symptom onset to diagnosis.
Exclude high-risk SMM patients from observation and consider early therapeutic intervention per current criteria.
by Edward Koo, Sarah Albert, Benjamin Patrick, Meriem Henia, Yona Rhiwi, Christopher McCudden, Victor Jimenez Zepeda, Irwindeep Sandhu, Michael Chu, Hira Mian, Alissa Visram
